This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Left sided colitis좌측 결장염

Contents and key points
ItemDetails
A. Classification codesICD-10: K51.5 (Left-sided colitis) | Special Copayment Reduction: V131 (severe intractable disease, 5 years)
B. SynonymsLeft-sided ulcerative colitis, sigmoid-descending colitis, distal colitis
C. Adult onsetAdult onset: high — accounts for about 20-30% of UC; involves the rectum up to the splenic flexure; occurs frequently in middle-aged and older adults
1. HistoryPart of the history of UC; recognition of the clinical importance of selective left-colon involvement after the introduction of the sigmoidoscope; differentiation of treatment strategy by extent of lesion
2. CausesSame as UC; specificity of the microbial and immune environment of the left colon up to the splenic flexure
3. GeneticsLoci common to UC such as HLA-DR2, IL-10R, ECM1; research on determinants of lesion extent is ongoing
4. General epidemiology20-30% of all UC; surgery rate is higher than proctitis and lower than pancolitis; colorectal cancer risk is intermediate
5. PathophysiologyMucosal barrier damage, stimulation by intestinal microbes, Th2/Th9 inflammatory mediation, left-colon-specific microbial environment
6. SymptomsBloody diarrhea, left lower abdominal pain, urgency; systemic symptoms may be more severe than in proctitis
7. SignsTenderness in the left lower and left abdomen, elevated fecal calprotectin, elevated CRP/ESR
8. ScreeningCalprotectin, total colonoscopy; confirmation of normal mucosa proximal to the splenic flexure is essential
9. DiagnosisTotal colonoscopy + tissue biopsy; confirm continuous inflammation distal to the splenic flexure and normal mucosa proximally
10. TreatmentOral 5-ASA ± enema; moderate to severe: steroids; refractory: immunosuppressants, biologics
11. PrognosisIntermediate prognosis; progression to pancolitis in about 20-30% within 10 years; surgery rate about 10-15% (10 years)
12. PreventionMesalazine maintenance, colorectal cancer surveillance (after 8-10 years), surveillance for progression to pancolitis
13. ReferencesSolberg et al. Scand J Gastroenterol 2009; Bewtra et al. Inflamm Bowel Dis 2007 and 8 others

1. History

Left-sided colitis is one of the classifications of ulcerative colitis (UC) by extent of lesion, in which the entire left colon from the rectum to the splenic flexure is involved. It includes sigmoiditis and is classified as E2 (left-sided colitis) in the Montreal classification (2006). Since 1859, when the history of UC began, selective left-colon involvement has been commonly observed in clinical practice, and the spread of the flexible sigmoidoscope in the 1960s-70s made it possible to directly observe and diagnose lesions distal to the splenic flexure.

The differentiation of UC treatment strategy by extent of lesion took place in the 1980s-90s. In left-sided colitis, the combination of rectal preparations (enemas) and oral mesalazine was established through clinical studies as effective. Unlike proctitis, in left-sided colitis the drug can reach as far as the splenic flexure with an enema, so the scope of topical therapy is wider. At the 2006 Montreal meeting, the extent of UC lesions was internationally standardized into three levels, E1 (proctitis), E2 (left-sided colitis), and E3 (pancolitis), which is now used in clinical practice and research. Since the 2010s, the introduction of biologics and small-molecule targeted therapies has expanded treatment options in all UC phenotypes, including left-sided colitis.


2. Causes

The cause of left-sided colitis is explained by the same multifactorial mechanism as other UC phenotypes such as pancolitis. Genetic predisposition, intestinal microbial abnormality, mucosal immune dysregulation, and environmental factors act in combination.

Left-colon-specific environment

The distribution of microbes in the human colon differs by anatomical location. The left colon (descending colon, sigmoid colon, rectum) has a longer fecal retention time than the right colon, higher fecal concentration, and a higher proportion of anaerobic bacteria. In addition, the left colon mucosa is composed of simple columnar epithelium, and there are studies suggesting that the expression pattern of tight junction proteins differs somewhat from that of the right colon. These anatomical and microbial characteristics partly explain the phenomenon that inflammation arises preferentially in the left colon and ends at the splenic flexure.

Immune and environmental factors

The protective effect of smoking in UC, the influence of environmental factors such as NSAIDs and antibiotics, stress, and diet operate in the same way in left-sided colitis. Defecation stimulation and mechanical pressure in the left colon may act as repeated mucosal irritation and lower the threshold for triggering inflammation.


3. Genetics

The genetic basis of left-sided colitis is largely shared with pancolitis and proctitis. Susceptibility loci common to UC, such as the HLA-DR2 allele, the IL-10 receptor gene, ECM1, and HNF4α, are also associated with left-sided colitis. GWAS are exploring associations between the extent of disease in UC and specific genotypes. Some studies have reported that HLA-DRB1*04:01 shows a specific association with left-sided colitis, but large-scale confirmation is still needed.

Genetic elements being studied as determinants of lesion extent include differences in IL-13 receptor (IL-13Rα1) expression, variation in expression of barrier-function genes of mucosal epithelial cells (CLDN1, CLDN4, etc.), and host genes that influence gut microbiome composition (FUT2, LCT, etc.). NUDT15 and TPMT gene polymorphisms are related to the risk of azathioprine toxicity, so genetic testing before treatment is clinically useful.


4. General epidemiology

Left-sided colitis accounts for about 20-30% of UC patients and, together with proctitis (30-40%) and pancolitis (20-30%), is one of the main UC phenotypes. It occurs mainly in adults, with a median age at diagnosis of 30-45 years. The incidence is relatively equal between men and women. In Korea as well, with the rising incidence of UC, the absolute number of patients with left-sided colitis is increasing, and the proportion of patients with severe disease activity is also on an upward trend.

Progression of lesions: About 20-30% of patients who start with left-sided colitis progress to pancolitis within 10 years after diagnosis. This is lower than the rate of proximal extension in proctitis (30-50%). The risk of progression to pancolitis is high when age at diagnosis is young, initial disease activity is high, and treatment response is incomplete.

Complications: Toxic megacolon can also occur in left-sided colitis, but less frequently than in pancolitis. The surgery rate is reported at about 10-15% within 10 years. The colorectal cancer risk is lower than in pancolitis but higher than in proctitis, so surveillance endoscopy is recommended 8-10 years after diagnosis.


5. Pathophysiology

The pathophysiology of left-sided colitis is the same as the general pathophysiology of UC. A continuous process leading from abnormal mucosal barrier function, invasion of the lamina propria by intestinal microbial antigens, and abnormal activation of innate and adaptive immune responses to persistent inflammation is manifested in the left colon.

Left colon mucosal barrier

Decreased expression of tight junction proteins and reduced goblet cell mucin secretion in the left colon mucosa increase mucosal permeability. The especially high fecal concentration and long contact time in the left colon cause repeated mucosal irritation and damage. IL-13-induced upregulation of claudin-2 mediates the increase in mucosal permeability, which is a result of a Th2-biased immune response.

Immune response

A Th2- and Th9-biased immune response predominates, with IL-5, IL-13, and IL-9 as the main cytokines. IL-13 increases epithelial cell apoptosis and induces ICAM-1 expression on vascular endothelium to promote neutrophil influx. As neutrophil infiltration of the crypts (cryptitis) and crypt abscess formation progress, crypt architectural distortion and mucosal ulceration occur. TNF-α and IL-6 induce a systemic inflammatory response.

The splenic flexure as a boundary

Why the splenic flexure so often acts as the anatomical boundary of UC lesions has not been fully elucidated. There are hypotheses that changes in the pattern of colonic blood supply at the splenic flexure, bowel motility characteristics, and changes in microbial distribution may contribute to its role as a boundary.


6. Symptoms

Because of more extensive colonic involvement than proctitis, the symptoms of left-sided colitis are more severe than in proctitis and milder than in pancolitis.

Gastrointestinal symptoms

Bloody diarrhea is the main symptom, with blood and mucus mixed in 4-8 loose stools per day. Left lower abdominal cramping pain is characteristic, worsening before defecation and relieved after defecation. Intestinal spasm from inflammation of the descending and sigmoid colon is the main pain mechanism. Urgency and tenesmus accompany it and are milder than in pancolitis. Because the right colon is normal, water and electrolyte absorption is partly preserved, so dehydration and electrolyte imbalance are less severe than in pancolitis.

Systemic symptoms

In moderately active left-sided colitis, fever (37.5-38.5°C), weight loss, and fatigue may occur. Iron deficiency anemia from chronic bleeding is common, and hypoalbuminemia is less common than in pancolitis but can occur at severe activity. Extraintestinal symptoms (arthralgia, skin symptoms, ocular symptoms) can occur and, although less frequent than in pancolitis, require clinical attention.


7. Signs

On physical examination, tenderness in the left lower and left abdomen is characteristically present. Bowel sounds are increased in the active phase, and decreased bowel sounds (with toxic megacolon) may appear at severe activity. Tachycardia, fever, and pallor (anemia) suggest severe disease activity.

Laboratory findings show elevated CRP, increased ESR, leukocytosis, and anemia. Fecal calprotectin rises to >150 μg/g or higher in active left-sided colitis and is useful for monitoring treatment response. Bloody discharge may be found on digital rectal examination. Endoscopic findings show continuous mucosal erythema, loss of vascular pattern, spontaneous bleeding, and ulcers from the rectum to the splenic flexure, with a transition to normal mucosa proximal to the splenic flexure.


8. Screening

Screening for left-sided colitis in the general population is not recommended. In patients complaining of bloody diarrhea and abdominal pain, a stepwise approach is taken: noninvasive screening followed by confirmation with endoscopy.

Noninvasive screening

Fecal calprotectin (>150 μg/g) is a sensitive marker of active intestinal inflammation. CRP and ESR reflect the systemic inflammatory response but have low specificity. Stool culture is performed together to exclude infectious colitis.

Imaging

Bowel ultrasound or CT enterography can noninvasively assess left colon inflammatory findings such as increased colonic wall thickness and increased blood flow. However, colonoscopy is essential for diagnostic confirmation and histopathological verification.

Colorectal cancer surveillance

Surveillance endoscopy for colorectal cancer is performed starting 8-10 years after diagnosis. The surveillance interval is differentiated according to risk, and if the disease has progressed to pancolitis, the surveillance criteria for pancolitis are applied.


9. Diagnosis

The diagnosis of left-sided colitis is made by total colonoscopy and tissue biopsy. The key is to confirm continuous mucosal inflammation distal to the splenic flexure and normal mucosa proximal to the splenic flexure. An inflammation distribution that starts in the rectum, progresses continuously upward, and ends at the splenic flexure is characteristic of left-sided colitis.

Biopsies are taken from the left colon including the splenic flexure and from normal segments (transverse colon, ascending colon, cecum) to confirm the anatomical boundary of inflammation and exclude Crohn's disease. Crypt architectural distortion, basal plasmacytosis, and neutrophil infiltration are observed in biopsies of the rectum, sigmoid colon, and descending colon, and normal histological findings confirmed at the transverse colon and above support the diagnosis of left-sided colitis.

Differentiation from Crohn's disease is important. In Crohn's disease, skip lesions, longitudinal ulcers, deep fissuring ulcers, perianal lesions, ileal involvement, and transmural granulomatous inflammation are characteristic. Indeterminate colitis is a diagnostic term used when differentiation is difficult.


10. Treatment

Treatment of left-sided colitis follows the general treatment principles of UC, and treatment intensity is determined by the extent of lesion and disease activity.

Mild to moderate left-sided colitis

Oral mesalazine (2.4-4.8 g/day) is the first-line treatment. The combination of oral mesalazine and mesalazine enema (1-4 g/day) yields a higher remission rate than oral administration alone. A mesalazine enema can deliver the drug as far as the sigmoid-descending colon and is suitable for topical treatment of left-sided colitis.

Moderate to severe left-sided colitis

Systemic steroids (prednisolone 40-60 mg/day) are used to induce remission. After response to steroids, taper and switch to 5-ASA maintenance. In steroid dependence or resistance, add azathioprine (2-2.5 mg/kg/day) or switch early to a biologic. Vedolizumab, infliximab, adalimumab, ustekinumab, and JAK inhibitors (tofacitinib, upadacitinib) are used in severe refractory disease.


11. Prognosis

The prognosis of left-sided colitis is intermediate between proctitis and pancolitis. With good remission maintenance therapy the course is relatively stable, but progression to pancolitis (about 20-30% per 10 years) worsens the prognosis. The surgery rate within 10 years is about 10-15%, and the colorectal cancer risk is lower than in pancolitis, but surveillance endoscopy is needed 8-10 years after diagnosis. When mucosal healing is achieved, the relapse and hospitalization rates fall markedly. Extraintestinal symptoms (arthropathy, skin symptoms, ocular symptoms) have an additional impact on quality of life.


12. Prevention

Primary prevention of left-sided colitis is not possible, but preventing relapse and preventing complications are the key to management. Long-term maintenance with oral mesalazine after achieving remission lowers the relapse rate. Maintaining mesalazine enemas 2-3 times a week is also effective for preventing relapse. Regular colorectal cancer surveillance endoscopy is performed starting 8-10 years after diagnosis, and surveillance intensity is raised if progression to pancolitis occurs. Manage relapse triggers such as smoking, NSAID use, irregular sleep, and severe stress. Patients on immunosuppressive treatment should follow the vaccination schedule for infection prevention.


13. References

  1. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis. Scand J Gastroenterol. 2009;44(4):431-440. DOI: 10.1080/00365520802600961.
  2. Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2007;5(5):597-601. DOI: 10.1016/j.cgh.2007.01.015.
  3. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5A-36A. PMID: 16151544.
  4. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384-413. DOI: 10.14309/ajg.0000000000000152.
  5. Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. J Crohns Colitis. 2017;11(6):649-670. DOI: 10.1093/ecco-jcc/jjx008.
  6. Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. DOI: 10.1038/s41572-020-0205-x.
  7. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450-1461. DOI: 10.1053/j.gastro.2020.01.006.
  8. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. DOI: 10.1136/gutjnl-2019-318484.
  9. Fumery M, Singh S, Dulai PS, et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts. Clin Gastroenterol Hepatol. 2018;16(3):343-356. DOI: 10.1016/j.cgh.2017.06.016.
  10. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):601-616. DOI: 10.1038/ajg.2011.67.